A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ICI and Viral Sign a Form a Strategic Alliance

ICI and Viral Sign strategic alliance will allow both companies to supply advanced screening systems intended to help slow the spread of infectious disease, including COVID-19.

Under the terms of the partnership, ICI will be the exclusive supplier of thermal-camera hardware, including ICI’s flagship FMX400, to Viral Sign’s future installations.  ICI is the supplier of choice to Fortune 500 companies, and to agencies of the U.S. federal government.  ICI’s hardware, which has received 510(k) clearance from the FDA, is renowned for its high quality and market-leading accuracy.

By partnering with Viral Sign, ICI expands and strengthens its distribution footprint, and significantly increases its reach into additional sites of care. The partnership is particularly relevant to employers with significant operational and economic risk due to infectious disease, including senior living, healthcare, food processing, manufacturing, education, and hospitality.

Viral Sign’s proprietary software algorithms help to identify the presence of virus, including COVID-19, in individuals prior to the onset of symptoms. Early identification of the potential for a contagious virus helps to ensure a safe work environment for employees and a safe return of employees to their families at the end of the workday. Viral Sign leverages the power of infrared imaging and an advanced screening algorithm to produce a comprehensive thermal signature of the face.

In real-time, Viral Sign’s advanced screening algorithm assesses the thermal signature across regions of interest in the face to identify patterns consistent with early, presymptomatic influenza-like illness, including COVID-19. Viral Sign represents a significant advance in screening science relative to body temperature or symptom-focused screening platforms.

The ICI/Viral Sign partnership is the result of a shared commitment to helping employers create a “site safe” workplace for employees, customers, and guests.  Working together, ICI and Viral Sign will also continue to develop software platforms that equip their customers to acquire and report real-time, secure insights about workplace safety both on-site and across multiple installations.  These development efforts will enable the acceleration of insights into human health that can transform the use of thermal technology for healthcare and wellness applications.

Gary Strahan, the CEO of ICI commented: “Viral Sign is a true innovator in the use of thermal technology for improvements in public health.  We are proud to be their exclusive supplier, and we look forward to working with Viral Sign to co-develop innovative world-class solutions to public health problems.”

Barry Hix, the CEO of Viral Sign said: “ICI’s name is synonymous with best-in-class accuracy and reliability in thermal-screening technology.  The rich data generated by ICI cameras align perfectly with Viral Sign’s software algorithms, enhancing our ability to provide predictive insights into the health of individuals, workforces, and communities.  We look forward to rolling out our ICI-powered systems into our client base, and to working with ICI on additional technology development.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy